MEREO BIOPHARMA (MREO)
(Delayed Data from NSDQ)
$4.15 USD
0.00 (0.00%)
Updated Jul 15, 2024 04:00 PM ET
After-Market: $4.15 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth NA Momentum NA VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MREO 4.15 0.00(0.00%)
Will MREO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MREO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MREO
MEREO BIOPHARMA (MREO) Loses -12.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat
MREO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ultragenyx's (RARE) Preliminary 2023 Revenues Disappoint
Ultragenyx (RARE) Q3 Earnings and Revenues Miss Estimates
Ultragenyx (RARE) Q2 Loss Wider Than Expected, Revenues Beat
Other News for MREO
Mereo BioPharma price target raised by $2 at Leerink, here's why
Biotech Alert: Searches spiking for these stocks today
Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market
Mereo BioPharma’s Public Offering and Strategic Underwriter Partnership
Baird starts Mereo at outperform, sees alvelestat as underappreciated